9/11
08:08 am
rxrx
Recursion Pharmaceuticals (NASDAQ:RXRX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Recursion Pharmaceuticals (NASDAQ:RXRX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
9/11
07:13 am
rxrx
Rating for RXRX
Medium
Report
Rating for RXRX
9/11
07:13 am
rxrx
Rating for RXRX
Medium
Report
Rating for RXRX